Pharmaceutical Technology17 小时
AKT-022 by Aquavit Pharmaceuticals for Unspecified Dermatological Disorders: Likelihood of ...
AKT-022 is under clinical development by Aquavit Pharmaceuticals and currently in Phase III for Unspecified Dermatological Disorders.
Pharmaceutical Technology17 小时
Opzelura by Incyte for Unspecified Dermatological Disorders: Likelihood of Approval
Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.